{"id":551241,"date":"2021-07-05T16:30:01","date_gmt":"2021-07-05T16:30:01","guid":{"rendered":"https:\/\/www.abnewswire.com\/pressreleases\/?p=551241"},"modified":"2021-07-05T16:30:01","modified_gmt":"2021-07-05T16:30:01","slug":"dystrophic-epidermolysis-bullosa-clinical-trial-pipeline-drugs-treatment-companies-and-emerging-therapies-by-delveinsight","status":"publish","type":"post","link":"https:\/\/www.abnewswire.com\/pressreleases\/dystrophic-epidermolysis-bullosa-clinical-trial-pipeline-drugs-treatment-companies-and-emerging-therapies-by-delveinsight_551241.html","title":{"rendered":"Dystrophic Epidermolysis Bullosa Clinical Trial, Pipeline Drugs, Treatment, Companies and Emerging Therapies by DelveInsight"},"content":{"rendered":"<div style=\"float:right; width:250px; padding:8px 10px 10px 10px;\"><a href=\"https:\/\/www.abnewswire.com\/uploads\/1625462714.jpeg\" style=\"border:none !important;\" target=\"_blank\" rel=\"nofollow\" ><img loading=\"lazy\" decoding=\"async\" class=\"alignnone size-medium wp-image-29\" title=\"Dystrophic Epidermolysis Bullosa Clinical Trial, Pipeline Drugs, Treatment, Companies and Emerging Therapies by DelveInsight\" src=\"https:\/\/www.abnewswire.com\/uploads\/1625462714.jpeg\" alt=\"Dystrophic Epidermolysis Bullosa Clinical Trial, Pipeline Drugs, Treatment, Companies and Emerging Therapies by DelveInsight\" width=\"225\" height=\"225\" style=\"padding:0px 0px 10px 10px; border:0 solid !important;\" \/><\/a><\/p>\n<div class=\"quotes\">\n<div>Dystrophic Epidermolysis Bullosa Pipeline<\/div>\n<\/div>\n<\/div>\n<p style=\"text-align: justify;\"><em>The Dystrophic Epidermolysis bullosa clinical pipeline comprises&nbsp;<strong>20+ notable therapeutic agents<\/strong>&nbsp;in different stages of clinical development varying from Gene therapies, Cell therapies, RNA\u2010targeting therapy, Protein therapies, Topical therapies, and Small molecules.<\/em><\/p>\n<p style=\"text-align: justify;\">&nbsp;<\/p>\n<p style=\"text-align: justify;\">DelveInsight&rsquo;s&nbsp;<strong>&lsquo;<a rel=\"nofollow\" href=\"https:\/\/www.delveinsight.com\/report-store\/dystrophic-epidermolysis-bullosa-pipeline-insight?utm_source=SatPR&amp;utm_medium=pressrelease&amp;utm_campaign=apr\">Dystrophic Epidermolysis Bullosa (DEB) Pipeline<\/a> Insights&rsquo;<\/strong>&nbsp;report presents a complete picture of the available therapies, Dystrophic Epidermolysis Bullosa emerging therapies in different phases of clinical development, key companies working in the Dystrophic Epidermolysis Bullosa pipeline domain, and future potential of the space.<\/p>\n<p style=\"text-align: justify;\">&nbsp;<\/p>\n<p style=\"text-align: justify;\"><strong>Some of the focal points picked from the&nbsp;<a rel=\"nofollow\" href=\"https:\/\/www.delveinsight.com\/report-store\/dystrophic-epidermolysis-bullosa-pipeline-insighthttps:\/www.delveinsight.com\/report-store\/dystrophic-epidermolysis-bullosa-pipeline-insight?utm_source=SatPR&amp;utm_medium=pressrelease&amp;utm_campaign=apr\">Dystrophic Epidermolysis Bullosa Pipeline<\/a>&nbsp;report:<\/strong><\/p>\n<ul style=\"text-align: justify;\">\n<li>Exhaustive analysis of the Dystrophic Epidermolysis Bullosa Pipeline demonstrates opportunities and scope in the future with the involvement of&nbsp;<strong>20+&nbsp;<\/strong>key players and&nbsp;<strong>20+&nbsp;<\/strong>key therapies.<\/li>\n<li>Key Dystrophic Epidermolysis Bullosa pipeline candidates such as&nbsp;<strong>genetically corrected cultured epidermal autograft<\/strong>,&nbsp;<strong>INM-755, B-VEC, FCX-007, AGLE-102, PTR-01, FCX-007<\/strong>, and others are under investigation in different phases of clinical trials for the treatment of Dystrophic Epidermolysis Bullosa.<\/li>\n<li>The entry of novel therapeutics is expected to boost the Dystrophic Epidermolysis Bullosa treatment market in the coming years.<\/li>\n<li>DelveInsight estimates that late-stage products such as&nbsp;<strong>EB-101<\/strong>,&nbsp;<strong>FCX-007<\/strong>, and&nbsp;<strong>B-VEC<\/strong>&nbsp;will have a major impact on the Dystrophic Epidermolysis Bullosa treatment market.<\/li>\n<li>Key prominent pharma players including&nbsp;<strong>Holostem Terapie Avanzate, InMed Pharmaceuticals, Krystal biotech, Castle Creek Biosciences, Zikani Therapeutics, Aegle Therapeutics, Phoenix Tissue Repair<\/strong>, among others are actively involved in strengthening the Dystrophic Epidermolysis Bullosa pipeline portfolio.<\/li>\n<li><strong>EB-101<\/strong>&nbsp;(<strong>Abeona Therapeutics<\/strong>) is an autologous, gene-corrected cell therapy for RDEB, a rare connective tissue disorder without an approved treatment in which patients suffer from severe epidermal wounds that impact the length and quality of their lives. The therapy is currently in the phase 3 stage of development to treat Dystrophic Epidermolysis Bullosa.<\/li>\n<\/ul>\n<p style=\"text-align: justify;\">&nbsp;<\/p>\n<p style=\"text-align: justify;\"><strong>Request for Sample to know more about the therapies expected to make grab the maximum patient pool @&nbsp;<a rel=\"nofollow\" href=\"https:\/\/www.delveinsight.com\/sample-request\/dystrophic-epidermolysis-bullosa-pipeline-insight?utm_source=SatPR&amp;utm_medium=pressrelease&amp;utm_campaign=apr\">https:\/\/www.delveinsight.com\/sample-request\/dystrophic-epidermolysis-bullosa-pipeline-insight<\/a><\/strong><\/p>\n<p style=\"text-align: justify;\">&nbsp;<\/p>\n<p style=\"text-align: justify;\">The Dystrophic Epidermolysis Bullosa Pipeline reports offer a holistic scenario of the ongoing clinical trials, partnerships taking place in the domain, recent happenings in space, and growth prospects across the Dystrophic Epidermolysis Bullosa domain.<\/p>\n<p style=\"text-align: justify;\">&nbsp;<\/p>\n<p style=\"text-align: justify;\"><strong>Dystrophic Epidermolysis Bullosa<\/strong><strong>: Overview<\/strong><\/p>\n<p style=\"text-align: justify;\">Epidermolysis Bullosa (EB) is a group of inherited disorders that causes blistering, which in several cases can be life-threatening to newborns and infants. It predominantly affects the skin and mucous membrane. A subtype of Epidermolysis Bullosa, Dystrophic Epidermolysis Bullosa (DEB) is characterized by the site of blister formation in the lamina densa within the basement membrane zone and the upper dermis.<\/p>\n<p style=\"text-align: justify;\">&nbsp;<\/p>\n<p style=\"text-align: justify;\"><strong><a rel=\"nofollow\" href=\"https:\/\/www.delveinsight.com\/report-store\/dystrophic-epidermolysis-bullosa-pipeline-insighthttps:\/www.delveinsight.com\/report-store\/dystrophic-epidermolysis-bullosa-pipeline-insight?utm_source=SatPR&amp;utm_medium=pressrelease&amp;utm_campaign=apr\">Dystrophic Epidermolysis Bullosa Pipeline Drugs<\/a><\/strong><\/p>\n<table style=\"width: 662px; height: 418px;\" border=\"1\" cellspacing=\"0\" cellpadding=\"0\">\n<tbody>\n<tr>\n<td valign=\"top\">\n<p><strong>Drug<\/strong><\/p>\n<\/td>\n<td valign=\"top\">\n<p><strong>Company<\/strong><\/p>\n<\/td>\n<td valign=\"top\">\n<p><strong>Phase<\/strong><\/p>\n<\/td>\n<td valign=\"top\" width=\"285\">\n<p><strong>MoA<\/strong><\/p>\n<\/td>\n<td valign=\"top\" width=\"86\">\n<p><strong>RoA<\/strong><\/p>\n<\/td>\n<\/tr>\n<tr>\n<td valign=\"top\">\n<p><strong>RGN-137<\/strong><\/p>\n<\/td>\n<td valign=\"top\">\n<p>RegeneRx Biopharmaceuticals<\/p>\n<\/td>\n<td valign=\"top\">\n<p>Phase II<\/p>\n<\/td>\n<td valign=\"top\" width=\"285\">\n<p>Angiogenesis inducing agents; Apoptosis inhibitors; Cell movement activators; Collagen stimulants<\/p>\n<\/td>\n<td valign=\"top\" width=\"86\">\n<p>Topical<\/p>\n<\/td>\n<\/tr>\n<tr>\n<td valign=\"top\">\n<p><strong>B-VEC<\/strong><\/p>\n<\/td>\n<td valign=\"top\">\n<p>Krystal biotech<\/p>\n<\/td>\n<td valign=\"top\">\n<p>Phase III<\/p>\n<\/td>\n<td valign=\"top\" width=\"285\">\n<p>Gene transference<\/p>\n<\/td>\n<td valign=\"top\" width=\"86\">\n<p>Topical<\/p>\n<\/td>\n<\/tr>\n<tr>\n<td valign=\"top\">\n<p><strong>FCX-007<\/strong><\/p>\n<\/td>\n<td valign=\"top\">\n<p>Castle<br \/> Creek Biosciences<\/p>\n<\/td>\n<td valign=\"top\">\n<p>Phase III<\/p>\n<\/td>\n<td valign=\"top\" width=\"285\">\n<p>Cell replacements; Collagen type VII replacements<\/p>\n<\/td>\n<td valign=\"top\" width=\"86\">\n<p>Intradermal<\/p>\n<\/td>\n<\/tr>\n<tr>\n<td valign=\"top\">\n<p><strong>Research programme-<\/strong><br \/> <strong>Ribosomal modulators<\/strong><\/p>\n<\/td>\n<td valign=\"top\">\n<p>Zikani Therapeutics<\/p>\n<\/td>\n<td valign=\"top\">\n<p>Preclinical<\/p>\n<\/td>\n<td valign=\"top\" width=\"285\">\n<p>Ribosomal RNA modulators<\/p>\n<\/td>\n<td valign=\"top\" width=\"86\">\n<p>NA<\/p>\n<\/td>\n<\/tr>\n<tr>\n<td valign=\"top\">\n<p><strong>AGLE-102<\/strong><\/p>\n<\/td>\n<td valign=\"top\">\n<p>Aegle Therapeutics<\/p>\n<\/td>\n<td valign=\"top\">\n<p>Phase I\/II<\/p>\n<\/td>\n<td valign=\"top\" width=\"285\">\n<p>Collagen type VII replacements<\/p>\n<\/td>\n<td valign=\"top\" width=\"86\">\n<p>Topical<\/p>\n<\/td>\n<\/tr>\n<tr>\n<td valign=\"top\">\n<p><strong>PTR-01<\/strong><\/p>\n<\/td>\n<td valign=\"top\">\n<p>Phoenix Tissue Repair<\/p>\n<\/td>\n<td valign=\"top\">\n<p>Phase II<\/p>\n<\/td>\n<td valign=\"top\" width=\"285\">\n<p>Collagen type VII replacements<\/p>\n<\/td>\n<td valign=\"top\" width=\"86\">\n<p>Intravenous<\/p>\n<\/td>\n<\/tr>\n<tr>\n<td valign=\"top\">\n<p><strong>TXA127<\/strong><\/p>\n<\/td>\n<td valign=\"top\">\n<p>Constant Therapeutics<\/p>\n<\/td>\n<td valign=\"top\">\n<p>Preclinical<\/p>\n<\/td>\n<td valign=\"top\" width=\"285\">\n<p>Proto-oncogene protein c-mas-1 agonists<\/p>\n<\/td>\n<td valign=\"top\" width=\"86\">\n<p>Intravenous<\/p>\n<\/td>\n<\/tr>\n<\/tbody>\n<\/table>\n<p style=\"text-align: justify;\">&nbsp;<\/p>\n<p style=\"text-align: justify;\"><strong>Request for Sample to know more @&nbsp;<a rel=\"nofollow\" href=\"https:\/\/www.delveinsight.com\/sample-request\/dystrophic-epidermolysis-bullosa-pipeline-insight?utm_source=SatPR&amp;utm_medium=pressrelease&amp;utm_campaign=apr\">https:\/\/www.delveinsight.com\/sample-request\/dystrophic-epidermolysis-bullosa-pipeline-insight<\/a><\/strong><\/p>\n<p style=\"text-align: justify;\">&nbsp;<\/p>\n<p style=\"text-align: justify;\"><strong>Dystrophic Epidermolysis Bullosa Therapeutics<\/strong><strong> Assessment<\/strong><\/p>\n<p style=\"text-align: justify;\">The Dystrophic Epidermolysis Bullosa Pipeline report presents a kaleidoscopic view of the DEB emerging novel therapies segmented by Stage, Product Type, Route of Administration, Molecule Type, Target, and Mechanism of Action.<\/p>\n<p style=\"text-align: justify;\"><strong>By Product Type<\/strong><\/p>\n<ul style=\"text-align: justify;\">\n<li>Mono<\/li>\n<\/ul>\n<p style=\"text-align: justify;\"><strong>By Stage<\/strong><\/p>\n<ul style=\"text-align: justify;\">\n<li>Discovery<\/li>\n<li>Pre-clinical<\/li>\n<li>IND<\/li>\n<li>Phase I<\/li>\n<li>Phase II<\/li>\n<li>Phase III<\/li>\n<li>Pre-registration<\/li>\n<\/ul>\n<p style=\"text-align: justify;\"><strong>By Molecule Type<\/strong><\/p>\n<ul style=\"text-align: justify;\">\n<li>Cell therapy<\/li>\n<li>Peptides<\/li>\n<li>Small interfering RNA<\/li>\n<li>Small molecule<\/li>\n<li>Gene therapy<\/li>\n<\/ul>\n<p style=\"text-align: justify;\"><strong>By Route of Administration<\/strong><\/p>\n<ul style=\"text-align: justify;\">\n<li>Oral<\/li>\n<li>Intradermal<\/li>\n<li>Intravenous<\/li>\n<li>Topical<\/li>\n<\/ul>\n<p style=\"text-align: justify;\"><strong>By Mechanism of Action<\/strong><\/p>\n<ul style=\"text-align: justify;\">\n<li>Collagen type VII replacements<\/li>\n<li>Gene Transference<\/li>\n<li>RNA interference<\/li>\n<li>Cannabinoid receptor agonists<\/li>\n<li>Ribosomal RNA modulators<\/li>\n<\/ul>\n<p style=\"text-align: justify;\"><strong>By Targets<\/strong><\/p>\n<ul style=\"text-align: justify;\">\n<li>Cannabinoid receptor<\/li>\n<li>Caspase 1<\/li>\n<li>Interleukin 1 beta<\/li>\n<li>Serine Protease targeted therapy<\/li>\n<\/ul>\n<p style=\"text-align: justify;\">&nbsp;<\/p>\n<p style=\"text-align: justify;\">&nbsp;<\/p>\n<p style=\"text-align: justify;\"><strong>Table of Contents<\/strong><\/p>\n<table style=\"width: 564px; height: 1054px; border-color: #000000; border-width: 1px; border-style: solid;\" border=\"1\" cellspacing=\"0\" cellpadding=\"0\">\n<tbody>\n<tr>\n<td valign=\"top\" width=\"24\">\n<p>1<\/p>\n<\/td>\n<td valign=\"top\" width=\"495\">\n<p>Report Introduction<\/p>\n<\/td>\n<\/tr>\n<tr>\n<td valign=\"top\" width=\"24\">\n<p>2<\/p>\n<\/td>\n<td valign=\"top\" width=\"495\">\n<p>Executive Summary<\/p>\n<\/td>\n<\/tr>\n<tr>\n<td valign=\"top\" width=\"24\">\n<p>3<\/p>\n<\/td>\n<td valign=\"top\" width=\"495\">\n<p>Dystrophic Epidermolysis Bullosa Disease Overview<\/p>\n<\/td>\n<\/tr>\n<tr>\n<td valign=\"top\" width=\"24\">\n<p>4<\/p>\n<\/td>\n<td valign=\"top\" width=\"495\">\n<p>DEB Pipeline Therapeutics Comparative Analysis<\/p>\n<\/td>\n<\/tr>\n<tr>\n<td valign=\"top\" width=\"24\">\n<p>5<\/p>\n<\/td>\n<td valign=\"top\" width=\"495\">\n<p>Dystrophic Epidermolysis Bullosa Therapeutic Assessment<\/p>\n<\/td>\n<\/tr>\n<tr>\n<td valign=\"top\" width=\"24\">\n<p>6<\/p>\n<\/td>\n<td valign=\"top\" width=\"495\">\n<p>Dystrophic Epidermolysis Bullosa &ndash; DelveInsight&rsquo;s Analytical Perspective<\/p>\n<\/td>\n<\/tr>\n<tr>\n<td valign=\"top\" width=\"24\">\n<p>7<\/p>\n<\/td>\n<td valign=\"top\" width=\"495\">\n<p>In-depth Commercial Dystrophic Epidermolysis Bullosa Assessment<\/p>\n<\/td>\n<\/tr>\n<tr>\n<td valign=\"top\" width=\"24\">\n<p>8<\/p>\n<\/td>\n<td valign=\"top\" width=\"495\">\n<p>Dystrophic Epidermolysis Bullosa Collaboration Deals<\/p>\n<\/td>\n<\/tr>\n<tr>\n<td valign=\"top\" width=\"24\">\n<p>9<\/p>\n<\/td>\n<td valign=\"top\" width=\"495\">\n<p>Late Stage Dystrophic Epidermolysis Bullosa Products (Phase III)<\/p>\n<\/td>\n<\/tr>\n<tr>\n<td valign=\"top\" width=\"24\">\n<p>10<\/p>\n<\/td>\n<td valign=\"top\" width=\"495\">\n<p>Mid-Stage Dystrophic Epidermolysis Bullosa Products (Phase II)<\/p>\n<\/td>\n<\/tr>\n<tr>\n<td valign=\"top\" width=\"24\">\n<p>11<\/p>\n<\/td>\n<td valign=\"top\" width=\"495\">\n<p>Early Stage Dystrophic Epidermolysis Bullosa Products (Phase I)<\/p>\n<\/td>\n<\/tr>\n<tr>\n<td valign=\"top\" width=\"24\">\n<p>12<\/p>\n<\/td>\n<td valign=\"top\" width=\"495\">\n<p>Pre-clinical and Discovery Stage DEB Products<\/p>\n<\/td>\n<\/tr>\n<tr>\n<td valign=\"top\" width=\"24\">\n<p>13<\/p>\n<\/td>\n<td valign=\"top\" width=\"495\">\n<p>Inactive Dystrophic Epidermolysis Bullosa Pipeline Products<\/p>\n<\/td>\n<\/tr>\n<tr>\n<td valign=\"top\" width=\"24\">\n<p>14<\/p>\n<\/td>\n<td valign=\"top\" width=\"495\">\n<p>Key Dystrophic Epidermolysis Bullosa Products<\/p>\n<\/td>\n<\/tr>\n<tr>\n<td valign=\"top\" width=\"24\">\n<p>15<\/p>\n<\/td>\n<td valign=\"top\" width=\"495\">\n<p>Unmet Needs<\/p>\n<\/td>\n<\/tr>\n<tr>\n<td valign=\"top\" width=\"24\">\n<p>16<\/p>\n<\/td>\n<td valign=\"top\" width=\"495\">\n<p>DEB Market Drivers and Barriers<\/p>\n<\/td>\n<\/tr>\n<tr>\n<td valign=\"top\" width=\"24\">\n<p>17<\/p>\n<\/td>\n<td valign=\"top\" width=\"495\">\n<p>Future Perspectives and Conclusion<\/p>\n<\/td>\n<\/tr>\n<tr>\n<td valign=\"top\" width=\"24\">\n<p>18<\/p>\n<\/td>\n<td valign=\"top\" width=\"495\">\n<p>Analyst Views<\/p>\n<\/td>\n<\/tr>\n<tr>\n<td valign=\"top\" width=\"24\">\n<p>19<\/p>\n<\/td>\n<td valign=\"top\" width=\"495\">\n<p>Key Dystrophic Epidermolysis Bullosa Companies<\/p>\n<\/td>\n<\/tr>\n<tr>\n<td valign=\"top\" width=\"24\">\n<p>20<\/p>\n<\/td>\n<td valign=\"top\" width=\"495\">\n<p>Appendix<\/p>\n<\/td>\n<\/tr>\n<\/tbody>\n<\/table>\n<p style=\"text-align: justify;\">&nbsp;<\/p>\n<p style=\"text-align: justify;\"><strong>About&nbsp;DelveInsight<\/strong><\/p>\n<p style=\"text-align: justify;\">DelveInsight is a leading Business Consultant and Market Research firm focused exclusively on life sciences. It supports Pharma companies by providing comprehensive end-to-end solutions to improve their performance. Get hassle-free access to all the healthcare and pharma market research reports through our subscription-based platform&nbsp;<strong>PharmDelve<\/strong>.<\/p>\n<p style=\"text-align: justify;\">&nbsp;<\/p>\n<p><span style='font-size:18px !important;'>Media Contact<\/span><br \/><strong>Company Name:<\/strong> <a href=\"https:\/\/www.abnewswire.com\/companyname\/delveinsight.com_56434.html\" rel=\"nofollow\">DelveInsight Business Research LLP<\/a><br \/><strong>Contact Person:<\/strong> Ankit Nigam<br \/><strong>Email:<\/strong> <a href=\"https:\/\/www.abnewswire.com\/email_contact_us.php?pr=dystrophic-epidermolysis-bullosa-clinical-trial-pipeline-drugs-treatment-companies-and-emerging-therapies-by-delveinsight\" rel=\"nofollow\">Send Email<\/a><br \/><strong>Phone:<\/strong> +19193216187<br \/><strong>Address:<\/strong>304 S. Jones Blvd #2432  <br \/><strong>City:<\/strong> Albany<br \/><strong>State:<\/strong> New York<br \/><strong>Country:<\/strong> United States<br \/><strong>Website:<\/strong> <a href=\"https:\/\/www.delveinsight.com\/report-store\/dystrophic-epidermolysis-bullosa-pipeline-insight\" target=\"_blank\" rel=\"nofollow\">https:\/\/www.delveinsight.com\/report-store\/dystrophic-epidermolysis-bullosa-pipeline-insight<\/a><\/p>\n<p><object type=\"text\/html\" data=\"https:\/\/www.delveinsight.com\/report-store\/dystrophic-epidermolysis-bullosa-pipeline-insight\" style=\"width:900px; height:400px;\"><\/object><img decoding=\"async\" src=\"https:\/\/www.abnewswire.com\/press_stat.php?pr=dystrophic-epidermolysis-bullosa-clinical-trial-pipeline-drugs-treatment-companies-and-emerging-therapies-by-delveinsight\" alt=\"\" width=\"1px\" height=\"1px\" \/><\/p>\n","protected":false},"excerpt":{"rendered":"<p>Dystrophic Epidermolysis Bullosa Pipeline The Dystrophic Epidermolysis bullosa clinical pipeline comprises&nbsp;20+ notable therapeutic agents&nbsp;in different stages of clinical development varying from Gene therapies, Cell therapies, RNA\u2010targeting therapy, Protein therapies, Topical therapies, and Small molecules. &nbsp; DelveInsight&rsquo;s&nbsp;&lsquo;Dystrophic Epidermolysis Bullosa (DEB) Pipeline &hellip; <a href=\"https:\/\/www.abnewswire.com\/pressreleases\/dystrophic-epidermolysis-bullosa-clinical-trial-pipeline-drugs-treatment-companies-and-emerging-therapies-by-delveinsight_551241.html\">Continue reading <span class=\"meta-nav\">&rarr;<\/span><\/a><\/p>\n","protected":false},"author":1,"featured_media":0,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[401,405,417,406,423],"tags":[],"class_list":["post-551241","post","type-post","status-publish","format-standard","hentry","category-Business","category-Health-Medicine","category-Marketing-Sales","category-Pharmaceuticals-Biotech","category-Professional-Services"],"_links":{"self":[{"href":"https:\/\/www.abnewswire.com\/pressreleases\/wp-json\/wp\/v2\/posts\/551241","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.abnewswire.com\/pressreleases\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.abnewswire.com\/pressreleases\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.abnewswire.com\/pressreleases\/wp-json\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/www.abnewswire.com\/pressreleases\/wp-json\/wp\/v2\/comments?post=551241"}],"version-history":[{"count":0,"href":"https:\/\/www.abnewswire.com\/pressreleases\/wp-json\/wp\/v2\/posts\/551241\/revisions"}],"wp:attachment":[{"href":"https:\/\/www.abnewswire.com\/pressreleases\/wp-json\/wp\/v2\/media?parent=551241"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.abnewswire.com\/pressreleases\/wp-json\/wp\/v2\/categories?post=551241"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.abnewswire.com\/pressreleases\/wp-json\/wp\/v2\/tags?post=551241"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}